UK Logs 30 Blood Clot Cases After AstraZeneca Covid-19 Vaccine Jabs

Source BBC

Source BBC

"I need to reiterate that at this time the risk of serious disease and death from Covid-19, if we experience a severe outbreak, especially among older Australians and those with serious health conditions, is far greater than the very small potential risk of a very rare clotting disorder associated with the vaccine", Kidd said.

The Netherlands also stopped using the vaccine for a period last month when there were earlier concerns about thrombosis, but started using it again when the European Medicines Agency said the vaccine is both safe and effective.

The Medicines and Healthcare Products Regulatory Authority said, "The benefits of vaccination against Covid-19 still outweigh any risks", and urged citizens to continue taking the vaccine. In total, some 400,000 people were given the AstraZeneca vaccine during the period the problems were reported.

Of the 18.1 million people who have had the Oxford vaccine in the United Kingdom, 30 people have developed blood clots, the medicines regulator has said.

The 30 reports of thrombosis, submitted by doctors or members of the public via a government website, came after 18.1 million doses of the vaccine had been administered to people in the country.

Australia's Deputy Chief Medical Officer says it is "likely" there is a link between the AstraZeneca vaccine and a Melbourne man being hospitalised with blood clots.

The Netherlands stopped vaccinations with AstraZeneca for people under the age of 60 after five new cases of thrombosis among women. The EMA is expected to announce updated advice on the issue on April 7.

Queensland finds 'missing link' case that sparked Brisbane lockdown
As Greater Brisbane residents scramble to revive their plans for the weekend, health authorities are urging people to be cautious. She is a nurse who became infected with Covid after treating a "superspreader" who arrived from Europe last month.

On Thursday, Germany's immunisation commission, the STIKO, recommended that anyone younger than 60 who received an initial vaccination with AstraZeneca be given either Pfizer-BioNTech or Moderna shots as their second vaccine doses.

But the regulator said the benefits of the vaccine in preventing coronavirus outweigh any risks and it urged the public to continue coming forward for the jab.

Last week, Britain announced a third coronavirus vaccine from USA firm Moderna (MRNA) will be rolled out in the United Kingdom from April and will join the AstraZeneca and Pfizer (PFE)/ BioNtech (BNTX) jabs already being offered on the NHS.

Adam Finn, a professor of pediatrics at the University of Bristol, said the "extreme rarity" of the blood-clotting events in the context of the millions of jabs administered in the United Kingdom makes the decision very straightforward.

Concerns have been raised about blood clots after a tiny proportion of cases arose among the tens of millions who have received the Oxford-AstraZeneca jab.

Figures showed that the United Kingdom has given a first dose of vaccine to 31.4 million people, or around 46 percent of its population, a much higher rate than the rest of Europe.

AstraZeneca said last month following United States efficiency trials that its vaccine is 79 percent effective at preventing the disease and does not increase the risk of blood clots. It also ordered 30 million doses of the Pfizer-BioNTech vaccine the same year.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.